Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells has a neutral effect on obesity-induced diabetic cardiomyopathy

Calligaris, Sebastiàn; Conget, Paulette

doi:10.4067/s0716-97602013000300005

Cited by 9 publications

(8 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was reported that intramyocardial transplantation of nondiabetic MSC has a protective effect on diabetic hearts . However, not all studies have consistently shown that stem cells from nondiabetic animals can improve the function of diabetic hearts . In this study, we tested the effects of diabetes on post‐AMI myocardial repair in the presence of stem cell therapy.…”

Section: Discussionmentioning

confidence: 99%

Role of SDF-1:CXCR4 in Impaired Post-Myocardial Infarction Cardiac Repair in Diabetes

Mayorga

Kiedrowski

McCallinhart

et al. 2017

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Diabetes is a risk factor for worse outcomes following acute myocardial infarction (AMI). In this study, we tested the hypothesis that SDF‐1:CXCR4 expression is compromised in post‐AMI in diabetes, and that reversal of this defect can reverse the adverse effects of diabetes. Mesenchymal stem cells (MSC) isolated from green fluorescent protein (GFP) transgenic mice (control MSC) were induced to overexpress stromal cell‐derived factor‐1 (SDF‐1). SDF‐1 expression in control MSC and SDF‐1‐overexpressing MSC (SDF‐1:MSC) were quantified using enzyme‐linked immunosorbent assay (ELISA). AMI was induced on db/db and control mice. Mice were randomly selected to receive infusion of control MSC, SDF‐1:MSC, or saline into the border zone after AMI. Serial echocardiography was used to assess cardiac function. SDF‐1 and CXCR4 mRNA expression in the infarct zone of db/db mice and control mice were quantified. Compared to control mice, SDF‐1 levels were decreased 82%, 91%, and 45% at baseline, 1 day and 3 days post‐AMI in db/db mice, respectively. CXCR4 levels are increased 233% at baseline and 54% 5 days post‐AMI in db/db mice. Administration of control MSC led to a significant improvement in ejection fraction (EF) in control mice but not in db/db mice 21 days after AMI. In contrast, administration of SDF‐1:MSC produced a significant improvement in EF in both control mice and db/db mice 21 days after AMI. The SDF‐1:CXCR4 axis is compromised in diabetes, which appears to augment the deleterious consequences of AMI. Over‐express of SDF‐1 expression in diabetes rescues cardiac function post AMI. Our results suggest that modulation of SDF‐1 may improve post‐AMI cardiac repair in diabetes. stem cells translational medicine 2018;7:115–124

show abstract

Section: Discussionmentioning

confidence: 99%

Role of SDF-1:CXCR4 in Impaired Post-Myocardial Infarction Cardiac Repair in Diabetes

Mayorga

Kiedrowski

McCallinhart

et al. 2017

Stem Cells Translational Medicine

View full text Add to dashboard Cite

show abstract

“…IV administration of allogeneic bone marrow-derived MSCs with a single dose of 0.5 × 10 6 or three consecutive monthly doses of 0.5 × 10 6 MSCs did not result in improved cardiac function when assessed 4 months later but rather has a neutral effect on DC. The observed effects may be as a result of the route, time, and dose used but possibly also to issues with efficient homing and engraftment of the tail vein administered cells (149). …”

Section: Msc-based Therapies For Other Diabetic Complicationsmentioning

confidence: 99%

Mesenchymal Stem Cell-Based Treatment for Microvascular and Secondary Complications of Diabetes Mellitus

et al. 2014

View full text Add to dashboard Cite

The worldwide increase in the prevalence of Diabetes mellitus (DM) has highlighted the need for increased research efforts into treatment options for both the disease itself and its associated complications. In recent years, mesenchymal stromal cells (MSCs) have been highlighted as a new emerging regenerative therapy due to their multipotency but also due to their paracrine secretion of angiogenic factors, cytokines, and immunomodulatory substances. This review focuses on the potential use of MSCs as a regenerative medicine in microvascular and secondary complications of DM and will discuss the challenges and future prospects of MSCs as a regenerative therapy in this field. MSCs are believed to have an important role in tissue repair. Evidence in recent years has demonstrated that MSCs have potent immunomodulatory functions resulting in active suppression of various components of the host immune response. MSCs may also have glucose lowering properties providing another attractive and unique feature of this therapeutic approach. Through a combination of the above characteristics, MSCs have been shown to exert beneficial effects in pre-clinical models of diabetic complications prompting initial clinical studies in diabetic wound healing and nephropathy. Challenges that remain in the clinical translation of MSC therapy include issues of MSC heterogeneity, optimal mode of cell delivery, homing of these cells to tissues of interest with high efficiency, clinically meaningful engraftment, and challenges with cell manufacture. An issue of added importance is whether an autologous or allogeneic approach will be used. In summary, MSC administration has significant potential in the treatment of diabetic microvascular and secondary complications but challenges remain in terms of engraftment, persistence, tissue targeting, and cell manufacture

show abstract

“…All data presented herein were obtained from refs. [44,54,55,70,72,74,75,78,88,95,96,98,[102][103][104][105][106][107][108][109][110][111]116,[119][120][121][124][125][126][127][128][129][130]132,[134][135][136][137][140][141][142][143][144][147][148][149][150][151][152][153][154]…”

Section: Resultsmentioning

confidence: 99%

“…[45,88,[92][93][94][99][100][101][102] Conversely, very long periods of diet exposure, that is, over 32 weeks, appear not to promote higher significant differences in the impairment of the animals' metabolic parameters compared to 12-24 weeks of exposure and seem to be less efficient in the development of MetS in mice (Table 4). [95][96][97][98]103] Van der Heijden et al evaluated C57BL/6J male mice fed with HFD (45% kcal from fat) for 24, 40, or 52 weeks and showed a rapid increase in body weight, which was significant from 12 weeks following a diet onward. Prolonged HFD feeding led to an additional, albeit slight, increase in body weight of up to 40 weeks and remained stable until the end of the study.…”

Section: Exposure Time To Dietmentioning

confidence: 99%

See 1 more Smart Citation

Modeling Diet‐Induced Metabolic Syndrome in Rodents

Leonardi

Gosmann

Zimmer

2020

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Standardized animal models represent one of the most valuable tools available to understand the mechanism underlying the metabolic syndrome (MetS) and to seek for new therapeutic strategies. However, there is considerable variability in the studies conducted with this essential purpose. This review presents an updated discussion of the most recent studies using diverse experimental conditions to induce MetS in rodents with unbalanced diets, discusses the key findings in metabolic outcomes, and critically evaluates what we have been learned from them and how to advance in the field. The study includes scientific reports sourced from the Web of Science and PubMed databases, published between January 2013 and June 2020, which used hypercaloric diets to induce metabolic disorders, and address the impact of the diet on metabolic parameters. The collected data are used as support to discuss variables such as sex, species, and age of the animals, the most favorable type of diet, and the ideal diet length to generate metabolic changes. The experimental characteristics propose herein improve the performance of a preclinical model that resembles the human MetS and will guide researchers to investigate new therapeutic alternatives with confidence and higher translational validity.

show abstract

Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells has a neutral effect on obesity-induced diabetic cardiomyopathy

Cited by 9 publications

References 26 publications

Role of SDF-1:CXCR4 in Impaired Post-Myocardial Infarction Cardiac Repair in Diabetes

Role of SDF-1:CXCR4 in Impaired Post-Myocardial Infarction Cardiac Repair in Diabetes

Mesenchymal Stem Cell-Based Treatment for Microvascular and Secondary Complications of Diabetes Mellitus

Modeling Diet‐Induced Metabolic Syndrome in Rodents

Contact Info

Product

Resources

About